Omeros Corporation Stock Prediction
AI-powered sentiment analysis and prediction trends for OMER, updated each market day.
OMER AI Sentiment
AI sees no strong directional signal for Omeros Corporation stock over the next 10 market days.
Prediction date: Oct. 13, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Sector
Exchange
Market Cap
$1,384,064,601
Cap Tier
Employees
175
Headquarters
SEATTLE, WA
Listed Since
Oct. 8, 2009
Website
OMER Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
OMER Volatility
Omeros Corporation has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
